New drug tricks the body into burning off fat
Researchers from Harvard University and the National Institutes of Health (NIH) have measured, for the first time, a repulsive quantum mechanical force that could be harnessed and tailored for a wide range of new nanotechnology applications. The study, led by Federico Capasso, Robert L. Wallace Professor of Applied Physics at Harvard’s School of Engineering and
Full Post: Researchers measure repulsive Casimir forces
French scientists have found a drug they say tricks the body into burning off fat - and it even works on a high-fat diet.
Reducing calorie consumption by about 20% has been shown to slow down the aging process, improve endurance and protect against diet-induced obesity and metabolic diseases such as diabetes.
Last year researchers demonstrated that these metabolic benefits can also occur with large doses of resveratrol, a substance naturally occurring in red wine.
The scientists from the University of Louis Pasteur say the drug SRT1720 which is a chemical cousin of resveratrol, protected mice against weight gain and insulin resistance. SRT1720 targets the protein SIRT1, which is thought to combat ageing.
The French team’s interest in the SIRT1 protein was prompted by earlier studies showing resveratrol countered some effects of a high-calorie diet through SIRT1. The study which was led by Professor Johan Auwerxand focused on creating a potent drug that would specifically target SIRT1 and came up with the drug SRT1720.
When they experimented with mice they found that a low dose of SRT1720 partially protected mice fed a high-fat diet, from gaining weight over a 15 week period of treatment - the drug worked by shifting the metabolism to a fat-burning mode that normally takes over only when energy levels are low and at higher doses, the drug completely prevented weight gain.
SRT1720 also improved the mice’s blood sugar tolerance and insulin sensitivity, which are important for warding off diabetes.
The mice on a high-fat diet treated with the higher drug dose did not become obese, and their triglyceride, cholesterol, fasting blood glucose and insulin levels were all reduced, they were also able to run approximately twice the distance as control animals in an endurance exercise test.
While the mice showed no sign of side effects, the scientists say further studies are needed to test the drug’s safety and efficacy before it could be used in humans.
Dr. Auwerx says unlike resveratrol, these new chemical entities target only the SIRT1 pathway, making them more selective and potent for achieving these metabolic benefits.
Experts researching obesity say the research is interesting though it is in the early stages and is welcome as an additional route of combating the obesity epidemic and related disease.
They say any anti-obesity drug should be used alongside dietary and lifestyle changes aimed at tackling obesity - the removal of the anti-obesity drug Acomplia, from the market amid safety concerns, means there are fewer drug options available.
The new drug was developed by Sirtris Pharmaceuticals, a ‘biotech’ start-up acquired by GlaxoSmithKline in April 2008.
The study appears in the current issue of the journal Cell Metabolism.
After you eat a burger and fries or other fat-filled meal, a protein produced by the liver may send a signal that fat is on the way, suggests a report in the December issue of the journal Cell Metabolism, a Cell Press publication. Researchers have found in mice that the liver produces a protein called
Full Post: Adropin protein produced by the liver sends signal that fat is on the way in response to high-fat foods
When an obesity drug called Leptin was first discovered by scientists 13 years ago, experts hoped the appetite-suppressing hormone would be a possible cure for obesity. Leptin failed to realise those expectations and it was discovered that overweight people became unresponsive to Leptin very quickly due to the development of resistance in the brain
Full Post: Fat busting drug Leptin could make a comeback
New evidence may explain why it is that we lose not only our youthful looks, but also our youthful pattern of gene activity with age. A report in the November 26th issue of the journal Cell, a Cell Press publication, reveals that a protein perhaps best known for its role in the life-extending benefits of
Full Post: Researchers provide new evidence that aging can be slowed
A protein known to play a role in development and the formation of organs is also an important factor in the control of obesity and diabetes, said researchers from Baylor College of Medicine in a report that appears in the current issue of the journal Cell Metabolism. Drs. Ming-Jer and Sophia Tsai, professors of molecular
Full Post: COUP-TFII plays pivotal role in obesity, metabolic syndrome
Genaera Corporation has announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally and peripherally to regulate insulin and
Full Post: Genaera starts trial of Trodusquemine in overweight and obese type 2 diabetes